- $2.95m
- -$5.59m
- $9.14m
- 17
- 44
- 12
- 13
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.73 | ||
| Price to Tang. Book | 1.73 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.42 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1811.64% | ||
| Return on Equity | -475.98% | ||
| Operating Margin | -847.42% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.37 | 4.75 | 5.68 | 7.44 | 9.14 | 5.52 | n/a | -25.57% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The Company's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).
Directors
- Fredric Eshelman CHM (73)
- Gail McIntyre PRE (58)
- Vinay Shah CFO (58)
- Reshma Rangwala OTH (43)
- Peter Ho DRC (59)
- John Hohneker DRC (61)
- Sigurd Kirk DRC (54)
- Amato Giaccia IND (62)
- Michael Rogers IND (61)
- Eric Zhang IND (39)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- December 10th, 2008
- Public Since
- March 20th, 2014
- No. of Shareholders
- 36
- No. of Employees
- 23
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 73,562,648
- Address
- RIVER OAKS TOWER, HOUSTON, 77098
- Web
- https://aravive.com/
- Phone
- +1 9363551910
- Auditors
- BDO USA, LLP
Upcoming Events for ARAV
Q1 2024 Aravive Inc Earnings Release
Similar to ARAV
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Aravive share price?
As of Today at 18:02 UTC, shares in Aravive are trading at $0.04. This share price information is delayed by 15 minutes.
How has the Aravive share price performed this year?
Shares in Aravive last closed at $0.04 and the price had moved by -97.65% over the past 365 days. In terms of relative price strength the Aravive share price has underperformed the S&P500 Index by -98.04% over the past year.
What are the analyst and broker recommendations for Aravive?
The overall consensus recommendation for Aravive is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Aravive dividend yield?
Aravive does not currently pay a dividend.
Does Aravive pay a dividend?
Aravive does not currently pay a dividend.
When does Aravive next pay dividends?
Aravive does not currently pay a dividend.
How do I buy Aravive shares?
To buy shares in Aravive you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Aravive?
As of the previous close price of $0.04, shares in Aravive had a market capitalisation of $2.95m.
Where are Aravive shares listed?
Here are the trading details for Aravive:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ARAV
What kind of share is Aravive?
Based on an overall assessment of its quality, value and momentum Aravive is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Aravive share price forecast for 2024?
The analyst consensus target price for shares in Aravive is $0.25. That is 523.44% above the last closing price of $0.04.
Analysts covering Aravive currently have a consensus Earnings Per Share (EPS) forecast of -$0.20 for the next financial year.
What is the trend in the Aravive share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aravive. Over the past six months, its share price has underperformed the S&P500 Index by -97.41%.
As of the last closing price of $0.04, shares in Aravive were trading -94.24% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Aravive PE Ratio?
The Aravive PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.04.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Aravive?
Aravive's management team is headed by:
- Fredric Eshelman - CHM
- Gail McIntyre - PRE
- Vinay Shah - CFO
- Reshma Rangwala - OTH
- Peter Ho - DRC
- John Hohneker - DRC
- Sigurd Kirk - DRC
- Amato Giaccia - IND
- Michael Rogers - IND
- Eric Zhang - IND